Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated